RECRUITING

First-in-Human Single and Multiple Dose of HL-400

Description

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.

Conditions

Parkinson Disease
Talk to us

Related Conditions:

Parkinson Disease

Study Overview

On this page

Study Details

Study overview

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.

A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Dose (SAD/MAD) Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics of HL-400 Following Oral Administration

First-in-Human Single and Multiple Dose of HL-400

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Baltimore

Pharmaron CPC, Inc., Baltimore, Maryland, United States, 21201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Are capable of giving written informed consent and complying with study procedures, schedule, requirements, and restrictions.
  • * Are between the ages of 18 and 65 years, inclusive, at screening.
  • * Female subjects have a negative serum hCG pregnancy test result at screening andDay （-1）, agree to refrain from ova donation for at least 3 months after the last dose, and willingness to comply with protocol-specified contraceptive methods.
  • * Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subject) plus an additional barrier method (female partner) of contraception for the duration of the study and for at least 3 months after last dosing; must also agree to refrain from sperm donation for at least 3 months after the last dose.
  • * Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs.
  • * Non-smoker for at least 6 months prior to screening.
  • * Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg.
  • * Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator.
  • * Pregnant (as determined by pregnancy test result) or breastfeeding women.
  • * History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance.
  • * Positive blood screen for human immunodeficiency virus (HIV 1/2), hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
  • * A positive screen for alcohol or drugs of abuse at screening or Day -1.
  • * An unwillingness or inability to comply with food and beverage restrictions during study participation.
  • * Volunteers who have participated in any investigational drug or device study within past 3 months prior to dosing.
  • * Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Highlightll Pharmaceutical (USA) LLC,

Study Record Dates

2026-02-27